Atrial Fibrillation

all catalysts(0)

nothing on the calendar yet

News(9)

• As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
  While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
  biospace · 7d ago
• BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
  Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…
  biospace · 12d ago
• BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
  BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.
  fiercebiotech · 12d ago
• Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
  Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.
  fiercebiotech · 12d ago
• Opinion: Beware the unintended consequences of testosterone screening for military servicemembers
  “I fear that the widespread rollout of testosterone screening may lead to some surprising and unintended consequences,” writes a urologist who studies testosterone.
  stat · 24d ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 1mo ago
• Edgewise heart drug passes key trial test
  Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.
  biopharma_dive · 1mo ago
• CLL-321 Trial Efficacy and Safety Results Analysis
  Phase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.
  onclive · 3mo ago
• Clinical Scenario Presentation and Treatment Approach for Progressive Disease
  Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.
  onclive · 3mo ago